Article citationsMore>>

van Stolk, R., Stoner, G., Hayton, W.L., Chan, K., DeYoung, B., Kresty, L., Kemmenoe, B.H., Elson, P., Rybicki, L., Church, J., Provencher, K., McLain, D., Hawk, E., Fryer, B., Kelloff, G., Ganapathi, R. and Budd, G.T. (2000) Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clinical Cancer Research, 6, 78-89.

has been cited by the following article: